BackNautilus Biotechnology Overview

Nautilus Biotechnology Total Assets

Track Nautilus Biotechnology's total assets ($150M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$148.92M
↓ 25.88% YoYΔ $-51.99M vs prior year quarter

Peer trimmed avg / median

Loading

Nautilus Biotechnology Total Assets History

Loading

Nautilus Biotechnology vs. peers: Total Assets Comparison

Loading

Nautilus Biotechnology Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Nautilus Biotechnology (NAUT) FAQ

Nautilus Biotechnology (NAUT) currently reports a total assets of $150M as of September 2026. That compares with $200M in the prior-year period — down 25.9% year over year. Use the charts on this page to explore Nautilus Biotechnology's total assets history and peer comparisons.

Nautilus Biotechnology's total assets decreased from $200M to $150M — a 25.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nautilus Biotechnology reported $150M in total assets as of September 2026. That compares with $200M in the prior-year period — down 25.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nautilus Biotechnology, and consider following NAUT for alerts when major investors trade the stock.

Nautilus Biotechnology is classified in the Healthcare sector. On total assets, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAUT with unrelated industries.